#antibodies

She has not experienced viral rebound and tests negative for HIV antibodies.

A combination of two antibodies, dubbed 3BNC117 and 10-1074, maintained viral suppression for a year in two people.

HIV mutates rapidly, enabling the virus to evade the common, narrowly targeted antibodies produced by most people with HIV.

An amfAR grant will help find out. Plus, the AIDS research group also awards three new Mathilde Krim HIV fellowships.

Researchers showed that B cells evolve after COVID-19 vaccination to help improve protection against SARS-CoV-2 over time.

The experimental vaccine regimen aims to train B cells to produce broadly neutralizing antibodies against HIV.

The findings suggest boosters not only lengthen immunity but help broaden and strengthen the immune response.

Different mechanisms suppressed the virus in each person.

Evidence is growing that contracting SARS-CoV-2 is generally as effective as vaccination at preventing COVID-19.

People who received the Moderna COVID-19 vaccine had strong immune memory of SARS-CoV-2 six months after vaccination.

About half of people hospitalized with COVID-19 had antibodies that could mistakenly attack the body’s own proteins and tissues.

With $600,000 in amfAR HIV grants, research teams explore CAR-T cells, bFAbs and CRISPR/Cas9 gene editing to eradicate the reservoir.

Early treatment is linked to a smaller viral reservoir, but blocking IL-10 and PD-1 might control the virus in those with chronic infection.

Two experimental vaccine approaches, using mRNA protein delivery and germline targeting, are in the early stages of development.

The CDC recommends that everyone ages 13 to 64 get a routine HIV test at least once.

The new prevention approach shows promise, but it isn’t heading to the clinic anytime soon.